Placenta-based therapies for the treatment of epidermolysis bullosa

Christopher Nevala-Plagemann, Catherine Lee, and Jakub Tolar
Stem Cell Institute and Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA

Abstract

Recessive dystrophic epidermolysis bullosa (RDEB) is a severe blistering skin disease caused by mutations in the COL7A1 gene. These mutations lead to decreased or absent levels of collagen VII at the dermal-epidermal junction. Over the past decade, significant progress has been made in the treatment of RDEB, including the use of hematopoietic cell transplantation, but a cure has proven elusive. Patients still experience life-limiting and life-threatening complications as a result of painful and debilitating wounds. The continued suffering of these patients drives the need to improve existing therapies and develop new ones. In this review, we will discuss how recent advances in placenta-, umbilical cord blood- and amniotic membrane-based therapies may play a role in the both the current and future treatment of RDEB.

Keywords

epidermolysis bullosa; umbilical cord blood; bone marrow; hematopoietic cell transplantation; mesenchymal stromal/stem cells; induced pluripotent stem cells

1 – Introduction

Epidermolysis bullosa (EB) is a heterogeneous group of predominantly genetically inherited blistering skin diseases. Generalized severe recessive dystrophic epidermolysis bullosa (RDEB), one of the major and most severe subtypes of EB, is caused by mutations in the gene COL7A1 that lead to decreased or absent levels of the extracellular matrix protein type VII collagen (C7) [1]. C7 is normally found near the dermal-epidermal junction (DEJ) and plays a role in the formation of anchoring fibrils that attach the epidermis to the dermis (Figure 1 A). Starting at birth, patients with RDEB experience severe, painful blistering of the skin from even minor trauma (Figure 1 B). Patients are also subject to mucosal lesions leading to esophageal strictures and difficulty maintaining proper nutrition. Additionally, as...
a likely result of the near constant inflammation associated with repeated cycles of blistering and healing, patients who survive beyond the first few years of life often experience aggressive and fatal forms of squamous cell carcinoma [2].

The devastating impact of RDEB on patients and their families has inspired intensive research efforts, but there is still no definitive cure for the disease. Several promising therapies have been developed to treat skin wounds by using intradermal injection or cutaneous application of fibroblasts, mesenchymal stromal/stem cells (MSCs), and recombinant C7. The limitation of these therapies is that they are unable to address the mucosal lesions and other systemic complications [3]. The need for a therapy that could address these challenges is what led to the first human trial of hematopoietic cell transplantation (HCT) for the treatment of RDEB [4]. Results from RDEB patients treated with HCT thus far are encouraging, but outcomes are still not perfect. Ultimately, the most effective approach to treating RDEB will probably require a combination of the local and systemic therapies being investigated (Figure 1 C) [5].

Recent advancements in the field of placenta-based therapies may be useful in refining and improving our current treatment strategies for RDEB. For example, in HCT umbilical cord blood (UCB) has several potential advantages over bone marrow (BM), including decreased collection risk to the donor compared to the harvesting of BM, decreased risk of infection transmission from donor to patient, a need for less stringent human leukocyte antigen (HLA)-matching requirements, and an overall lower risk of graft-versus-host disease (GvHD). Additionally, UCB is becoming more readily available as cord blood banks grow and techniques for ex vivo expansion of hematopoietic cells improve [6; 7]. Likewise, the amount of research being done on non-HCT UCB-based therapies is increasing [8; 9; 10]. In this review, we will discuss these advances as they relate to both the current and future treatment of RDEB.

2 – Hematopoietic cell transplantation for epidermolysis bullosa

2.1 Preclinical studies

For many years it was widely believed that the use of BM transplantation in the setting of a protein deficiency would only be feasible if the deficient protein was soluble, e.g., iduronidase deficiency in mucopolysacharidosis type I [11]. This notion was challenged when Chino et al. [12] demonstrated that an in utero BM transplant could be used to improve survival in a murine model of RDEB. In a simultaneous and independent study, Tolar and colleagues performed HCT on a murine model of RDEB using various populations of stem cells and found that 15% of mice that received a transplant of signaling lymphocyte activating molecule-positive (SLAM+) (CD150+) cells survived long term compared to untreated pups, which typically died within the first days of life. Furthermore, an immunohistochemical examination of the skin of these transplanted mice showed that donor cells homed to the skin and produced C7 [13]. The ability to use hematopoietic stem cell therapy to treat an extracellular matrix disease was confirmed again by Fujita et al., who demonstrated that BM transplantation improved survival in a murine model of a related genodermatosis, junctional EB [14].

Cytotherapy. Author manuscript; available in PMC 2016 June 01.
2.2 Clinical trials

Based on the encouraging results of the preclinical experiments described above, a clinical trial of HCT for EB was initiated by Wagner et al. [4]. As of 2014, 26 individuals with severe RDEB have been treated with allogeneic HCT. Stem cell sources have varied, with 15 individuals receiving HLA-matched or partially HLA-matched, related BM cells; six receiving HLA-matched or partially HLA-matched unrelated BM cells; and five receiving partially HLA-matched UCB cells. The pre-transplantation conditioning regimen has also varied, with half of the patients receiving standard myeloablative conditioning (MAC) and half receiving reduced intensity conditioning (RIC). In an abstract by Tolar et al. submitted to the Society of Investigative Dermatology Annual Meeting 2015, it is reported that a significant majority of the engrafted individuals have shown marked biochemical (increased C7 expression at the DEJ), ultrastructural (increased number of anchoring fibrils, albeit with immature architecture), and/or clinical improvements (decreased body surface area affected by disease and increased resistance to blistering).

2.3 Explaining what works

Although there is clear evidence suggesting that HCT may be an effective treatment for RDEB, the exact mechanism behind the observed therapeutic effect remains a mystery. Initially it was thought that improved outcomes might be related either to some aspect of the preconditioning regimen used to prepare patients for HCT or to the higher level of care patients received during and after transplant. However, many of the treated RDEB patients have shown symptomatic improvement for several years following HCT, long after immunosuppressive medications used for preconditioning (typically six months after HCT) or increased care during transplant would be expected to have an effect. It seems more likely that the therapeutic effect of HCT for RDEB is truly due to characteristics of the transplanted donor cells [15]. Supporting this theory is the identification of donor cell chimerism in the skin of several RDEB patients following transplant [4].

Several previous studies showed donor cell chimerism in the epithelium of transplant recipients (Table 1), so the observation that donor cells homed to and engrafted in the skin of RDEB patients after HCT was not unexpected. In 2007, Murata et al. had noted the presence of both donor-derived keratinocytes and endothelial cells in the skin of 18 patients who experienced GvHD following sex-mismatched HCT [16]. This study also observed a higher number of donor cells where the skin experienced the greatest wounding due to GvHD, leading Murata et al. to hypothesize that donor cells were playing a role in epidermal and microvessel repair [16].

A few years later, Khan et al. identified the presence of donor-derived epithelial cells in nasal scrapings taken from 60 patients who had received allogeneic HCT. The median percentage of donor epithelial cells increased from 0% on day seven post transplant, to 2.8% at three months post transplant, to 8.5% at 12–22 years post-transplant, suggesting that donor cell migration to the epithelium and engraftment therein occurs most rapidly during the first few months following transplant [17].
A study by Tamai et al. found that, when given a green fluorescent protein (GFP) BM transplant, mice with skin grafts had a high number of donor-derived epithelial cells near the grafts. These epithelial cells were found to be derived from Lin-/?PDGFRα+ cells and were believed to home to sites of skin grafting due to the release of high mobility box group 1 protein by skin grafts. In the same study, donor cell chimerism was not identified in the skin of wounded mice that did not receive a skin graft [18]. Expanding on this work, Iinuma et al. used flow cytometry to identify donor-derived cells that migrated to RDEB mouse skin grafted onto a wild-type mouse following a GFP BM transplant. Non-hematopoietic BM cells, including Lin-/?PDGFRα+ mesenchymal cells, were found in the RDEB skin graft and via real-time PCR were shown to highly express C7. Interestingly, when mice were given a systemic administration of the CXCR4 antagonist AMD3100, migration of PDGFRα+ cells to skin grafts was significantly reduced and deposition of C7 along the DEJ of the RDEB skin grafts, observed in the absence of AMD3100, was interrupted suggesting that PDGFRα+ cells may play a crucial role in the wound healing observed after transplant [19].

Another important observation to include in this discussion is that the degree of donor chimerism observed in the skin of RDEB patients who received HCT was high (on average 20%) [4] suggesting that migration and/or engraftment of donor derived cells is enhanced by some characteristic of actively wounded skin. One possible explanation is that the epidermal stem cell niches in RDEB patients are depleted of cells due to rapid skin cell turnover caused by frequent blistering/healing and are therefore more suitable for the engraftment of donor cells. Another possibility is that the active wounds of RDEB patients secrete homing molecules that actively recruit donor cells to sites of injured tissue [15].

The donor cells found in the epidermis of RDEB patients receiving HCT were of both hematopoietic and non-hematopoietic origin [4]. Since hematopoietic cells have not been shown to express significant amounts of C7, it is reasonable to hypothesize that these non-hematopoietic cells are at least partially responsible for the increased deposition of C7 at the DEJ [15]. It is possible that HSCs are capable of transdifferentiation into epidermal stem cells, however it is the view of the authors that a population of stem cells contained within transplanted cells are intrinsically capable of both homing to wounded skin and secreting C7. Additional preclinical research will help to elucidate the answers to these mechanistic questions and, most importantly, will allow us to improve upon what has turned out to be a promising therapy for RDEB.

3 – Placenta-based therapies and epidermolysis bullosa

3.1 Mesenchymal stromal/stem cells

MSCs can be found in multiple adult and fetal tissues, and have been shown to have extensive regenerative and immunomodulatory properties. Although strictly defined by criteria set forth by the International Society of Cellular Therapy in 2006 [20], recent studies are refining our working definition of MSCs [21]. Much of our current knowledge is based on MSCs isolated from BM, adipose tissue, or peripheral blood (PB), however, interest in MSCs derived from UCB is increasing [22; 23; 24], partly due to the fact that isolation of UCB MSCs is easier than isolation of MSCs from other sources [25; 26]. Additionally, UCB MSCs have been shown to have a faster population doubling time in vitro [27] and are...
more readily available than other sources of MSCs due to the increasing prevalence of cord blood banking. In addition to UCB, MSCs can also be isolated from the placenta, umbilical artery or vein, cord lining and Wharton’s jelly [28]. It is important to note that although MSCs from these various sources are often collectively referred to as UCB MSCs, differences between them have been demonstrated [29].

With regards to the treatment of skin diseases, it has now been well documented that MSCs play a role in the normal physiological process of wound healing [29; 30] and can be used therapeutically to accelerate wound healing [31; 32]. At least two studies have specifically evaluated the effect of cutaneous MSC transplantation in the context of RDEB. In a study by Alexeev et al., autologous MSCs were transplanted into the skin of a murine model of RDEB. Immunofluorescence analysis of the skin of pups that survived three weeks post-transplant revealed patchily distributed C7, estimated to be about 15% that of wild type C7 levels. Remarkably, when the skin of these transplanted pups was subjected to a mechanical stress test, separation along the DEJ did not occur suggesting that even a partial restoration of C7 could provide clinically meaningful benefits [33]. Around the same time, Congent et al. injected BM MSCs from an unrelated donor intradermally near the wounds of two patients with RDEB. At one week post-treatment, the DEJ was observed to be intact and at 12 weeks post-treatment, C7 was identified in MSC treated skin. However, the therapeutic effect was transient, as re-ulceration occurred approximately four months following treatment in both patients [34].

While the studies referenced and described above help demonstrate both the potential and limitations of MSC-based therapies for wound healing, they all used BM MSCs. A study by Luo et al. specifically evaluated the potential of UCB MSCs to promote cutaneous wound healing. In their study, they isolated MSCs from human UCB, labeled them with 5-bromodeoxyuridine, and then injected them into a murine cutaneous wounding model. Skin wound healing was accelerated compared to controls and labeled epidermal cells derived from the injected UCB MSCs were identified in the skin near the wound site [35]. While this study showed that UCB MSCs are similar to BM MSCs in their capacity to accelerate wound healing, it did not provide any data suggesting whether one source of MSCs might be superior to the other.

Fortunately, a recent study by Kim et al. directly compared the wound healing potential of MSCs isolated from UCB, BM, and PB. They injected $3 \times 10^6$ cells from each MSC source subcutaneously into a murine excisional skin wounding model and then used a photometric analysis to evaluate the healing response for 14 days. On day 8, average relative wound closure for UCB, BM and PB MSC treated wounds was significantly different at 58%, 42%, and 22%, respectively. Based on a histological analysis, the authors also noted that both granulation tissue and re-epithelialization of UCB MSC-treated wounds appeared to be thicker and larger than those treated with BM or PB MSCs [36]. Cumulatively, these studies (summarized in Table 2) provide evidence to support the use of MSC-based therapies for the treatment of RDEB and, although less definitively, suggest that UCB MSCs may have an advantage over MSCs isolated from other tissues.
While in general the molecular characteristics of MSCs isolated from UCB are very similar to those isolated from other sources [13; 37], differences have been identified. In the Kim et al. study described above, a proteomic analysis of UCB, BM, and PB-derived MSCs revealed several differentially regulated proteins. Specifically, cytoskeletal proteins were found to be upregulated in PB MSCs (tubulin alpha 1 C chain, annexin A2, laminin B1, PDZ domain-containing protein GIPC1 and actin) and BM MSCs (tubulin alpha 1 C chain and annexin A2), and antioxidant and detoxification proteins were found to be upregulated in both BM MSCs (carbonyl reductase, heat shock protein beta 1, glutathione S-transferase Mu3 and glutathione S-transferase omega-1) and UCB MSCs (heat shock protein beta 1, glutathione S-transferase Mu3, glutathione S-transferase omega-1, S-formylglutathione hydrolase, annexin A1 and chloride intracellular channel protein 4) (35). Likewise, an earlier study used serial analysis of gene expression to compare cultured UCB MSCs isolated from the umbilical vein to cultured BM MSCs and identified several genes related to matrix remodeling and the tumor necrosis factor alpha angiogenesis related pathways that were expressed either exclusively or at significantly greater levels in UCB MSCs. These genes included CXCL6, interleukin (IL)-8, IL-1 receptor-like ligand, matrix metalloproteinase-1, integrin alpha-3, CXCL1, and pentraxin 3 [38]. A recent reanalysis of this data combined with a proteomic analysis identified 67 differentially expressed proteins, most of which were upregulated in UCB MSCs when compared to BM MSCs [39].

Finally, it is worth discussing the immune-modulating characteristics of MSCs. Numerous studies have shown that MSCs play a role in both the adaptive and innate immune systems [13; 40; 41; 42]. Based on these immunoregulatory properties, it was hypothesized that MSCs could be useful in the treatment of disorders such as GvHD. While early studies on the use of MSCs for GvHD were promising [43; 44], the results of subsequent clinical trials were less so [45]. Although the therapeutic advantage was less definitive than had been originally hoped, the use of MSCs for GvHD is still being actively investigated, refined and optimized. Interestingly, a few studies have shown that UCB- and placental-derived MSCs may have significantly greater immunosuppressive potential than other sources of MSCs [31; 46; 47; 48]. While large head-to-head clinical trials would be needed to prove that UCB MSCs are in fact superior to other sources of MSCs for the treatment of GvHD, these findings are very encouraging, particularly because, due to the repetitive cycles of blistering and healing, RDEB patients live in a near-constant state of inflammation. As our knowledge of the immune-modulating properties of MSCs improves, we may discover novel indications for the use of MSC-based therapies in the treatment of RDEB and other inflammatory conditions.

### 3.2 Unrestricted somatic stem cells

An additional population of stromal stem cells that can be found in UCB are known as unrestricted somatic stem cells (USSCs) [49]. Similar to MSCs, USSCs have a greater in vitro expansion potential than BM MSCs [50], express C7, are capable of differentiating into keratinocytes in vitro, and have been shown to promote wound healing after migrating to the skin after both intradermal and tail vein injections in a mouse model [51]. These characteristics certainly make USSCs an interesting candidate for the development of future...
EB treatments; however, future research is needed to determine what therapeutic advantages, if any, USSCs would have over MSCs.

### 3.3 Induced pluripotent stem cells

One of the most promising developments in the treatment of EB is the combined use of induced pluripotent stem (iPS) cells and gene editing. Cells isolated from a variety of sources can be reprogrammed to pluripotency using the canonical Yamanaka factors Oct4, Sox2, Klf4, and c-Myc [52]. If correction of the \textit{COL7A1} mutation in these cells were followed by directed differentiation, it would provide a patient-specific and renewable source of cells for transplant. Tolar et al. demonstrated the derivation of iPS cells from both fibroblasts and keratinocytes taken from a patient with RDEB [53]. These iPS cells were capable of differentiation into both hematopoietic and non-hematopoietic lineages, and were shown to form skin-like structures in mice. Osborn et al. expanded on this work by using TALEN-based gene editing to correct the \textit{COL7A1} mutation in fibroblasts taken from an RDEB patient. These gene-corrected fibroblasts were then used to derive and expand an iPS cell line to a level that could theoretically be used in a human transplant [54]. There are also examples of RDEB patients with spontaneous reversion of the \textit{COL7A1} mutation, where self-corrected keratinocytes produce functional C7 in patches of healthy-looking skin. These corrected keratinocytes could be reprogrammed into iPS cells capable of differentiation into epidermal and hematopoietic cell lineages, setting the stage for autologous cellular therapies using this ‘natural’ gene therapy [55]. While the advantage of transplanting hematopoietic cells is their ability to target the systemic manifestations of RDEB, the increased expression of C7 found in epidermal stem cells may make them an equally viable candidate for cellular therapies. Yet another approach, taken by Sebastiano et al., used adeno-associated virus to correct the \textit{COL7A1} mutation in patient-derived iPS cells that could then be differentiated into epithelial sheets of keratinocytes [56]. Overall, iPS cell generation and gene editing techniques are improving at a rapid pace and the ability to translate these technologies into clinical therapies is now becoming a reality. In September 2014 the first clinical trial with human iPS cells began, when autologous iPS cells derived from six patients with age-related macular degeneration were differentiated into retinal pigment epithelial cell sheets for surgical implantation in the eye [57]. If this study establishes the safety and feasibility of using iPS cells in humans, trials using gene-corrected iPS cells may not be far behind.

Placental cells could also potentially play a role in these developing iPS cell therapies. It has been well documented that iPS cells can be produced from cord blood cells [58; 59; 60]. In addition to the ease with which iPS cells can be generated from cord blood, they have been generated from cords stored as long as 23 years [61], making the vast stores of banked cord blood cells available for treatments. For hematopoietic cell transplants, the neonatal nature of cord blood cells makes them immunologically immature and therefore safer to use for partially HLA-matched transplants without a corresponding increase in GvHD [62]. Although obtaining an adequate dose of hematopoietic stem cells (HSCs) for an adult patient from a single cord blood unit is challenging, \textit{ex vivo} expansion of cord blood cells is possible [63; 64]. An additional advantage is that they are obtained from neonates, so they may have not had time to accumulate as many nuclear and somatic mutations as aged cells [65; 66]. A recent study by Tomassetti et al. found that 65% of the differences in cancer
risk among different tissue types could be explained by the rate at which the stem cells in those particular tissues divide [67]. As HSCs are highly proliferative, undergoing $10^{11}$ divisions during a lifetime, the use of neonatal HSCs obtained from cord blood for HCT is further supported. Combining cord blood HCTs with the synergistic action of AMD3100 and tacrolimus, which has been found to augment cutaneous wound healing by mobilizing endogenous HSCs, could be the key to effectively resolving the skin lesions of patients with RDEB [68; 69].

Generating iPS cells from cord blood could offer an epigenetic advantage as well. It has been shown that after reprogramming to pluripotency, low passage iPS cells retain epigenetic marks based on the cell type they were derived from. This bias can be substantial, as Kim et al. found when iPS cells derived from keratinocytes were compared to those derived from cord blood. This study found that iPS cells derived from keratinocytes have 9.4 times the potential to form keratinocytes, while iPS cells derived from cord blood have increased potential to form cells of myeloid lineage [70]. In addition to the retention of DNA methylation profiles and chromatin marks, the miRNA network unique to the starting cell type remains intact for low passage iPS cells [71]. Thus far, attempts to derive fully engraftable HSCs from human iPS cells have failed, possibly due to the complex microenvironment necessary for the development of functional HSCs in vivo [72]. Differentiating low passage iPS cells derived from cord blood could take advantage of this epigenetic and miRNA bias and, in combination with the co-culture method developed by Suzuki et al., has the potential to improve the yield of CD34+ HSCs that can repopulate the BM after transplant [72].

### 3.4 Amniotic membrane grafting

Despite the progress made in systemic therapies, the treatment of individual wounds still remains a major aspect of the care of RDEB patients. Amniotic membrane grafts are a type of biological dressing that has previously been used to successfully treat leg ulcers and burns. A recent retrospective chart review by Lo et al. evaluated the use of amniotic grafting to treat chronic wounds in two patients with RDEB. Based on a qualitative wound score, a significant clinical response was noted in four of eight treated wounds, with complete healing in one [73].

### 3.5 Cord blood platelet gel

Similarly, autologous PB platelet-rich gel has also previously been shown to be both safe and effective at treating cutaneous wounds [74]. However, recent research has shown that cord blood platelet gels (CBPGs) may be better suited to the treatment of skin wounds. In addition to being more easily obtained than autologous PB platelet gels, CBPGs have a lower risk of infection and contain a higher concentration of the growth factors believed to be responsible for the regenerative effect of platelet gels. These growth factors include platelet-derived growth factor, transforming growth factor, fibroblast growth factor, and vascular endothelial growth factor [75]. In a recent case report, severe chronic wounds in three RDEB patients were treated with CBPGs for three weeks. Wounds treated with CBPGs healed faster than untreated control wounds and relapses were not observed in the four weeks following treatment [76].
While the results of both amniotic membrane transplants and CBPGs are encouraging, additional prospective studies are needed before any definitive conclusions about their effectiveness can be made [77]. Further, it is important to consider the potential impact of these treatments within the context of the pathophysiology of RDEB. Even if future studies clearly demonstrate that these therapies are superior to current wound care strategies in EB (which they likely are), without C7 to provide stability at the DEJ, new wounds will inevitably arise. As discussed in a recent editorial, the true potential of these treatments may lie in combination with other therapies currently being developed [5]. For example, the growth factors secreted by CBPGs could potentially be used to enhance the homing and engraftment potential of both local and systemic cellular therapies.

5 – Conclusions

Over the past decade, significant advances have been made in the treatment of EB. Patients who were once offered nothing beyond palliative measures are now being offered hope based on the early success of HCT. Despite this progress, many obstacles still remain and, as is often the case with complex diseases, the optimal treatment of RDEB will ultimately rely on the combined effects of multiple therapies. Recent advances in placenta-based therapies are promising, both as a way to improve upon existing treatments and as novel therapies (Figure 2). Furthermore, while the focus of this review has been on the application of placenta-based therapies for the treatment of RDEB, it is important to remember that there are many genetic skin disorders, some of which, like RDEB, are both debilitating and currently without an effective cure. It is therefore imperative that, as we continue to advance our collective knowledge through the treatment of RDEB, we make an effort to apply what we have learned to the treatment of additional diseases.

Acknowledgements

We apologize to the authors whose work could not be quoted because of space constraints and thank Nancy Griggs Morgan for editorial assistance. JT is supported in part by R01 AR063070, R01 AR059947, DOD W81XWH, EB Research Partnership, EB Medical Research Foundation, DEBRA, and the Sohana Research Fund.

Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>BM</td>
<td>bone marrow</td>
</tr>
<tr>
<td>C7</td>
<td>type VII collagen</td>
</tr>
<tr>
<td>CBPG</td>
<td>cord blood platelet gel</td>
</tr>
<tr>
<td>DEJ</td>
<td>dermal-epidermal junction</td>
</tr>
<tr>
<td>EB</td>
<td>epidermolysis bullosa</td>
</tr>
<tr>
<td>GvHD</td>
<td>graft versus host disease</td>
</tr>
<tr>
<td>HCT</td>
<td>hematopoietic cell transplantation</td>
</tr>
<tr>
<td>HLA</td>
<td>human leukocyte antigen</td>
</tr>
<tr>
<td>HSC</td>
<td>hematopoietic stem cell</td>
</tr>
</tbody>
</table>
IL interleukin
iPS induced pluripotent stem
MAC myeloablative conditioning
MSC mesenchymal stromal/stem cell
PB peripheral blood
RDEB recessive dystrophic epidermolysis bullosa
RIC reduced intensity conditioning
UCB umbilical cord blood
USCC unrestricted somatic stem cell

References


Figure 1.
Combination therapy for epidermolysis bullosa.
Figure 2.
Placenta-based therapies for the treatment of recessive dystrophic epidermolysis bullosa.
Table 1

Human studies demonstrating donor cell chimerism following transplant.

<table>
<thead>
<tr>
<th>Subject</th>
<th>Chimerism</th>
<th>Additional Findings</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with GvHD following sex-mismatched HCT</td>
<td>Donor-derived keratinocytes and endothelial cells found in the skin</td>
<td>Increased level of chimerism in regions with severe GvHD</td>
<td>Murata et al. 2007 [16]</td>
</tr>
<tr>
<td>Patients who received HCT</td>
<td>Donor-derived epithelial cells found in nasal scrapings</td>
<td>Engraftment occurred most rapidly during first few months following transplant</td>
<td>Khan et al. 2010 [17]</td>
</tr>
<tr>
<td>Patients with severe RDEB</td>
<td>Donor-cell chimerism detected in the skin</td>
<td>Hematopoietic and nonhematopoietic donor cells identified</td>
<td>Wagner et al. 2010 [4]</td>
</tr>
</tbody>
</table>
Table 2
Studies supporting the use of UCB MSC-based therapies for the treatment of RDEB.

<table>
<thead>
<tr>
<th>Purpose of Study</th>
<th>Subject</th>
<th>Results</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Determine the effect of cutaneous BM MSC transplantation on wound healing in RDEB</td>
<td>Murine model of RDEB</td>
<td>Patchily distributed C7 at DEJ 3 weeks post transplant; increased DEJ stability at 12 weeks</td>
<td>Alexeev et al. 2011 [33]</td>
</tr>
<tr>
<td>Determine the effect of cutaneous BM MSC transplant on wound healing in RDEB</td>
<td>2 patients with RDEB</td>
<td>Accelerated wound healing compared to controls at 1 week post transplant; increased C7 at DEJ at 12 weeks; recurrent ulceration at 16 weeks</td>
<td>Conget et al. 2010 [34]</td>
</tr>
<tr>
<td>Determine the effect of cutaneous UCB MSC transplantation on wound healing</td>
<td>Murine wounding model</td>
<td>Significantly increased wound healing compared to controls; identification of donor derived epidermal cells near wound sites</td>
<td>Luo et al. 2010 [35]</td>
</tr>
<tr>
<td>Compare the effect of UCB, BM, and PB MSC transplantation on cutaneous wound healing</td>
<td>Murine wounding model</td>
<td>Significantly greater wound healing UCB MSC treated wounds compared to BM or PB MSCs; increased granulation tissue and rep epithelialization in UCB MSC treated wounds</td>
<td>Kim et al. 2012 [36]</td>
</tr>
</tbody>
</table>